Author: openjargon

Yesterday, Droneshield Ltd (ASX: DRO) shares closed 5.54% higher at $3.81 a piece.

Tuesday’s uptick means the shares are now 14% higher over the year-to-date and 218% higher than this time last year.

As an Australian defence technology company specialising in counter-drone systems and electronic warfare solutions, Droneshield is one of very few ASX shares which have actually benefitted from rising geopolitical volatility and an ongoing war between the US and Iran. 

In a conflict situation, drones are used for everything from surveillance to direct strikes. This creates a huge demand for counter-drone systems like the ones Droneshield specialises in. This is why governments are hiking their spend on defence, with a focus on anti-drone defence systems. 

And the demand isn’t expected to dwindle the minute the US and Iran reach a peace agreement either. While conflict boosts demand, Droneshield has also announced several new military contracts and orders recently, showing that this is likely a long-term shift in how nations defend themselves.

If I bought $5,000 worth of Droneshield shares 5 years ago, what are they worth now?

It’s interesting to look back at how quickly Droneshield shares have climbed in value over the past six or 12 months. But, what about those investors which invested cash into the stock several years ago and have sat on it ever since?

Droneshield shares first listed on the ASX in June 2016 at 20 cents per share after raising $7 million through an IPO. The stock closed its first day of trading at 30 cents per share.

Fast forward to April 2021 and Droneshield shares had dropped to around 18 cents per share, shedding around 40% of its value. The shares didn’t start gaining traction until early 2024.

While a 218% annual share price increase is impressive, those gains are eclipsed by Droneshield’s 2,016.67% increase over the past five years!

That means that $5,000 invested into Droneshield shares 12 months ago is now worth $15,875. But $5,000 invested into Droneshield shares five years ago is now worth an enormous $105,833.50.

Can the shares keep climbing higher?

Yes, but not at the same rate they have climbed over the past five years.

TradingView data shows two out of three analysts have a strong buy rating on the defence stock. The third analyst has recently downgraded their rating to neutral. 

The average target price for DroneShield shares over the next 12 months is $4.50 a piece. At the time of writing, that implies an 18% upside ahead for investors. Some are more bullish and expect the shares to jump 31% to $5 in the next 12 months. 

The post $5,000 invested in Droneshield shares 5 years ago is now worth… appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today
• Where I’d invest $3,000 in ASX growth shares now
• These are the 10 most shorted ASX shares
• Looking for another DroneShield? Check out this buy-rated ASX defence stock

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and is short shares of DroneShield. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The idea of earning a second income from ASX shares is appealing.

But for many investors, it also feels risky. Chasing high returns or speculative stocks can lead to volatility and sleepless nights.

The good news is that building a second income does not have to involve taking big risks. In fact, a more measured approach can often be more effective over the long term.

Start with the right goal

The first step is to be clear about what you are trying to achieve.

If the goal is income, then the focus should be on building a portfolio that generates reliable cash flow, not just capital gains.

This means thinking in terms of yield. For example, a portfolio with a 5% average dividend yield would require around $400,000 to generate $20,000 per year.

Once you understand the target, the path becomes much clearer.

Focus on reliable businesses

Not all dividends are equal. Companies that consistently generate strong cash flow and have a history of paying dividends are often better suited for income-focused portfolios.

These tend to include sectors like banking, telecommunications, infrastructure, and consumer staples. They may not always deliver the fastest growth, but they often provide more predictable income. Think Telstra Group Ltd (ASX: TLS) and Woolworths Group Ltd (ASX: WOW).

The key is reliability. A slightly lower yield from a stable ASX share is often better than a high yield that may not be sustainable.

Use diversification to reduce risk

One of the simplest ways to lower risk is diversification.

By spreading investments across different sectors and companies, you reduce the impact of any single underperformer.

This can be done through a mix of individual ASX shares or by using ETFs that focus on income-producing assets like the Vanguard Australian Shares High Yield ETF (ASX: VHY).

Diversification helps create a more stable income stream over time.

Reinvest before you rely on it

In the early stages, it can be tempting to start using dividend income straight away.

But reinvesting those payments can significantly accelerate progress.

By reinvesting dividends, you increase the size of your portfolio, which in turn increases future income. This compounding effect can make a meaningful difference over time.

Once the portfolio reaches a comfortable size, you can then begin to draw on the income.

Be patient and stay consistent

Building a second income is not something that happens overnight.

It requires regular contributions, a long-term mindset, and the discipline to stay invested through market cycles.

There will be periods where dividends fluctuate or markets become volatile. But over time, a portfolio built on quality and consistency can deliver reliable income.

A steady path to financial freedom

You do not need to take big risks to build a meaningful second income from ASX shares.

By focusing on quality businesses, reinvesting early, and staying consistent, it is possible to create a portfolio that delivers steady cash flow over time.

It may not be the fastest approach, but it is one that many investors find far more sustainable.

The post How to build a second income from ASX shares without taking big risks appeared first on The Motley Fool Australia.

More reading

• Where I’d invest on the ASX for passive income right now
• Up 22%, are Telstra shares still worth a buy?
• Buy, hold, sell: Xero, Woolworths, CBA shares
• Why this is the best income ASX ETF for retirees
• Vanguard ETF dividends to be paid today

Motley Fool contributor James Mickleboro has positions in Woolworths Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Telstra Group and Woolworths Group. The Motley Fool Australia has recommended Vanguard Australian Shares High Yield ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Sometimes ASX exchange traded funds (ETFs) can make investing far more efficient.

Instead of building a portfolio company by company, a single ETF can provide exposure to entire industries or global leaders. The key is choosing funds that tap into areas with strong long-term demand.

Here are three ETFs that approach that challenge from very different angles.

BetaShares Global Cybersecurity ETF (ASX: HACK)

The first ASX ETF to consider is the BetaShares Global Cybersecurity ETF.

Cybersecurity sits behind almost every part of the modern economy. As more systems move online, protecting data and infrastructure becomes essential.

This bodes well for the fund’s holdings, which are leading the way in protecting us all online. This includes names such as Palo Alto Networks (NASDAQ: PANW), CrowdStrike (NASDAQ: CRWD), and Fortinet (NASDAQ: FTNT).

Palo Alto Networks stands out as a key player in this space. The company has evolved from traditional firewall solutions into a broader platform that secures cloud environments, networks, and endpoints.

BetaShares Nasdaq 100 ETF (ASX: NDQ)

Another ASX ETF for investors to consider this week is the BetaShares Nasdaq 100 ETF.

This fund provides exposure to some of the largest and most influential companies in the world, many of which are driving technological change.

Its holdings include tech giants such as Apple (NASDAQ: AAPL), NVIDIA (NASDAQ: NVDA), and Amazon (NASDAQ: AMZN).

Apple remains one of the most important companies in the index. Beyond hardware, it has built an ecosystem of services and software that continues to generate recurring revenue. Its scale, brand strength, and integration across devices give it a unique position in the global technology landscape.

VanEck Video Gaming and Esports ETF (ASX: ESPO)

A third ASX ETF for investors to consider is the VanEck Video Gaming and Esports ETF.

Gaming has become one of the largest forms of entertainment globally, with growth driven by digital distribution, online play, and in-game monetisation.

This ETF provides investors with access to the leading players in the industry. This includes companies such as Tencent Holdings (SEHK: 700), Nintendo, and Take-Two Interactive (NASDAQ: TTWO).

Take-Two Interactive is a good example of how the industry is evolving. Known for major franchises like Grand Theft Auto, the company has increasingly focused on recurring revenue through online gameplay and content updates. This shift creates longer engagement cycles and more predictable earnings over time.

This fund was recently recommended by the team at VanEck.

The post Wondering which ASX ETFs to buy? Try these top picks appeared first on The Motley Fool Australia.

More reading

• Best and worst case scenarios this week for global equities: Expert
• Buy these exciting ASX ETFs for AI exposure
• This ASX shares and ETF mix could be the key to early retirement
• Looking for ASX ETFs to buy and hold? Here are 3 top picks
• 5 excellent ASX ETFs to buy next week

Motley Fool contributor James Mickleboro has positions in BetaShares Nasdaq 100 ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon, Apple, BetaShares Global Cybersecurity ETF, BetaShares Nasdaq 100 ETF, CrowdStrike, Fortinet, Nvidia, Take-Two Interactive Software, and Tencent and is short shares of Apple and BetaShares Nasdaq 100 ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Nintendo and Palo Alto Networks. The Motley Fool Australia has positions in and has recommended BetaShares Nasdaq 100 ETF. The Motley Fool Australia has recommended Amazon, Apple, CrowdStrike, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There are a lot of options for investors on the ASX 200 index.

To narrow things down, let’s take a look at what Morgans is saying about three popular ASX 200 shares.

Does it rate them as buys, holds, or sells? Let’s find out:

Collins Foods Ltd (ASX: CKF)

Morgans is feeling positive about this KFC-focused quick service restaurant operator ahead of its upcoming results.

While it has trimmed its estimates to reflect a number of items, this is partially offset by a stronger than expected performance in the Australian market.

As a result, it has retained its buy rating with a slightly reduced price target of $12.50. It said:

We revise our CKF forecasts ahead of the FY26 result in June, trimming underlying NPAT to reflect deferred store openings, reset German acquired store economics, and a lower EU SSS assumption to better capture the Netherlands-skewed mix for FY26, partially offset by a marginal AU SSS upgrade on sustained KFC Australia momentum. We maintain our BUY recommendation and reduce our price target to $12.50 (from $12.70).

Netwealth Group Ltd (ASX: NWL)

This investment platform provider delivered a third-quarter update that was slightly ahead of expectations.

And with the new quarter starting strongly for financial markets, Morgans appears to believe it could build on this.

This has seen the broker put an accumulate rating and $29.00 price target on Netwealth’s shares. It commented:

NWL’s 3Q26 net-flows of $3.96bn came in modestly ahead of expectations, however market volatility during the period eroded this solid performance to see 3Q26 FUA ending the quarter flat QoQ at A$125.8bn, (vs. Consensus A$129.8bn). Despite ongoing volatility and uncertainty tied to a US/Middle East conflict and a potential resolution, market momentum has recovered from peak pessimism in the March Quarter, with the ASX All Ordinaries +5.6% month-to-date in April’26, which will have seen FUA growth momentum improve post quarter end.

Looking through this near-term volatility NWL remains on track deliver solid growth FY26F and well placed to capitalised on the long runway of opportunity ahead. We retain our ACCUMULATE rating, with a Price target of $29.00/sh.

Pro Medicus Ltd (ASX: PME)

Finally, after adjusting its model for Pro Medicus to reflect more achievable growth estimates, the broker continues to see a lot of value in its shares.

The broker has retained its buy rating on Pro Medicus shares with a reduced price target of $210.00. It commented:

In this note, we deploy a new PME model where we have deliberately set a lower bar. Our remodelled estimates prioritise achievability over optimism, staging implementation revenue conservatively and mark FX to spot. We see this as the right framework for a stock where sentiment has been fragile.

On the business operations front, the story remains untarnished. Contract newsflow since February has been exceptional: ~$100m in wins and renewals, all at higher pricing, with cardiology upsell gaining traction. The demand story is not in question. We re-emphasise our positive long-term conviction on the name although lower our valuation to reflect current but potentially fleeting headwinds. Our target price is reduced to A$210 p/s and we retain our Buy recommendation.

The post Buy, hold, sell: Collins Foods, Netwealth, and Pro Medicus shares appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Collins Foods, Domino’s, and Guzman Y Gomez shares
• Experts say this ASX financials stock could soar up to 40%
• Where I’d invest $3,000 in ASX growth shares now
• Want to double your money in 2026? This is what I’d buy
• Leading brokers name 3 ASX shares to buy today

Motley Fool contributor James Mickleboro has positions in Collins Foods and Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Netwealth Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Netwealth Group. The Motley Fool Australia has recommended Collins Foods and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are lucky enough to have $3,000 to invest in the share market, then it could be worth considering ASX exchange traded funds (ETFs).

ETFs allow investors to spread their capital across different regions, sectors, and investment styles in a simple and efficient way.

But which ones could be top picks for investors in April and May? Let’s take a look at three ASX ETFs that were recently recommended by the team at BetaShares:

BetaShares Global Cash Flow Kings ETF (ASX: CFLO)

The first ASX ETF to consider is the BetaShares Global Cash Flow Kings ETF.

This fund focuses on companies generating strong and consistent free cash flow. That emphasis can highlight businesses with proven models and the ability to reinvest, pay dividends, or reduce debt.

Its holdings include ASML Holding (NASDAQ: ASML), Visa (NYSE: V), and Palantir Technologies (NASDAQ: PLTR).

Palantir is a notable inclusion. The company specialises in data analytics and artificial intelligence platforms used by governments and enterprises. Its software is designed to handle complex datasets and support decision-making at scale. As AI adoption increases, demand for these types of tools is expected to grow.

BetaShares MSCI Emerging Markets Complex ETF (ASX: BEMG)

Another ASX ETF to consider is the BetaShares MSCI Emerging Markets Complex ETF.

This fund provides broad exposure to emerging markets, which are being shaped by powerful long-term trends such as a rising middle class, urbanisation, and accelerating digital transformation.

The BetaShares MSCI Emerging Markets Complex ETF gives investors access to more than 1,000 companies across over 20 countries, including regions in Asia, Latin America, Eastern Europe, and Africa. These are markets that can be difficult and costly to access directly.

Its holdings include Taiwan Semiconductor Manufacturing Company (NYSE: TSM), Alibaba Group (NYSE: BABA) and SK Hynix.

Alibaba is one of the most prominent technology platforms in emerging markets. The company operates across ecommerce, logistics, and cloud computing, and continues to invest in artificial intelligence through initiatives such as its Qwen large language models and AI Cloud services.

BetaShares S&P/ASX Australian Technology ETF (ASX: ATEC)

A third ASX ETF to consider is BetaShares S&P/ASX Australian Technology ETF.

It provides exposure to Australia’s leading technology companies, many of which are expanding globally.

Its holdings include Pro Medicus Ltd (ASX: PME), WiseTech Global Ltd (ASX: WTC), and Xero Ltd (ASX: XRO).

Pro Medicus is a standout name in the portfolio. The company develops imaging software used by hospitals and healthcare providers worldwide. Its solutions are known for high performance and scalability, and the business has built a strong reputation in a specialised but growing market.

The post 3 ASX ETFs to invest $3,000 into in April and May appeared first on The Motley Fool Australia.

More reading

• Best and worst case scenarios this week for global equities: Expert
• 2 ASX ETFs that could be a perfect for a tech rally
• 5 excellent ASX ETFs to buy next week
• ASX ETFs to target if you expect struggling sectors to rebound
• 3 BetaShares ASX ETFs I’d buy in April for long-term growth

Motley Fool contributor James Mickleboro has positions in Pro Medicus, WiseTech Global, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ASML, Palantir Technologies, Taiwan Semiconductor Manufacturing, Visa, WiseTech Global, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Alibaba Group and Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia has recommended ASML, Pro Medicus, and Visa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Here are the top 10 ASX 200 shares today appeared first on The Motley Fool Australia.

More reading

• Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today
• 3 ASX 200 shares tipped to tumble 10% (or more) in the next 12 months
• National Storage REIT: Court approves Brookfield-led buyout
• Atlas Arteria shares: Q1 2026 toll revenue ticks higher
• Mineral Resources launches US$1.3bn notes offer to cut debt costs

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Block and DroneShield and is short shares of DroneShield. The Motley Fool Australia has recommended Eagers Automotive Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX stock Cleanaway Waste Management Ltd (ASX: CWY) is starting to catch investors’ attention again.

Shares in the waste management giant rose 3% to $2.385 during Tuesday afternoon trade, extending a recent recovery that has pulled the stock further away from its five-year lows.

While Cleanaway is still down around 8% year to date, lagging the S&P/ASX 200 Index (ASX: XJO), which is up roughly 2.5%, sentiment appears to be shifting.

So, what’s driving the interest in this ASX stock today?

Tighten cost, drive efficiency

The key catalyst is Cleanaway’s refreshed strategy, which is giving investors a clearer path to improved profitability. On Tuesday, the ASX stock unveiled its “Blueprint 2030 2.0” plan, focused on margin expansion, stronger cash flow, and more disciplined execution.

Management highlighted that underlying EBIT has already lifted 60% since FY22, suggesting the business has momentum heading into its next phase.

The updated strategy rests on three pillars: lifting customer value, optimising the branch network, and using data and digital tools to boost performance. In practice, that means targeting higher-value revenue, tightening costs, and investing in automation and analytics to drive efficiency.

Sales overhaul

One of the standout initiatives of the ASX stock is a major overhaul of its sales approach. Cleanaway is rolling out a centralised “One Sales Engine” model aimed at improving customer retention and increasing cross-selling opportunities.

At the same time, its ongoing digitisation program is targeting better fleet utilisation, real-time tracking, and enhanced safety outcomes.

There’s also a significant push in its hazardous waste division. Cleanaway is streamlining its site network while expanding into higher-margin technical services and decommissioning work. These areas are expected to see strong demand growth in the years ahead.

What next for the ASX stock?

Looking forward, management has set some ambitious targets. The company is targeting at least 260 basis points of margin expansion and 10% to 15% EPS growth in FY27 as cost cuts take hold. It’s also pushing to deliver steadier free cash flow through tighter capital allocation and better asset use.

Cleanaway is backing its integrated network and growing use of technology to strengthen its lead in sustainable waste. Especially in higher-value areas like hazardous waste.

Fluctuating fuel cost

Of course, challenges remain. The ASX stock is still navigating a volatile operating environment, including fluctuating fuel costs and broader economic uncertainty. Management is focused on tightening operational efficiency, optimising its fleet, and using procurement strategies to better manage costs.

For investors, the story is shifting from turnaround to execution. Cleanaway’s strategy has laid out a clearer roadmap for growth. And if it can deliver, the recent price recovery of the ASX stock may have further to run.

The post New strategy sparks rebound in this $5bn ASX stock – what’s next? appeared first on The Motley Fool Australia.

More reading

• Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today
• Cleanaway Waste Management shares in focus as strategy refresh targets margin growth
• What is Morgans saying about A2 Milk and these ASX shares?
• What does this broker have to say about Cleanaway Waste Management and Capstone Copper shares?
• Why is this $5 billion ASX stock sliding to a 52-week low today?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

PYC Therapeutics Ltd (ASX: PYC) recently had some good news from one of its drug trials, which has boosted its share price.

But there’s plenty more upside to be had, according to the analyst team at Canaccord Genuity, which has a buy rating on the stock and a bullish price target, which we’ll get to shortly.

Encouraging progress

Firstly, let’s have a look at what was announced recently.

PYC said it is progressing an investigational drug candidate known as PYC-001, which “addresses the underlying cause of a blinding eye disease called Autosomal Dominant Optic Atrophy (ADOA)”.

The company announced on April 15 that the Safety Review Committee overseeing the Phase 1 Single Ascending Dose (SAD) study of PYC-001 had reviewed the data from the first four weeks of the trial and approved progression to a multiple dose study.

The company added:

PYC is now evaluating the safety and efficacy profile of repeat doses of PYC-001 in a global Multiple Ascending Dose (MAD) study of PYC-001 in patients with ADOA. The objective of this study is to establish clinical proof-of-concept prior to progression of the drug candidate into a global registrational trial directed towards supporting a New Drug Application for PYC-001 in ADOA. Safety and efficacy outcomes from this study will be presented throughout 2026 and 2027.

The company said ADOA affects one in every 35,000 people and there are currently no approved treatment options available.

Broad portfolio attractive

The Canaccord team said there was a lot to like about PYC; however, they were more focused on its potential kidney treatment.

They said in a research note to clients:

Following a large raise (A$600.5m, +400m shares), PYC is now sufficiently cashed up to progress its pipeline of RNA assets across its retinal, kidney and neuro indications. Like many, we are most intrigued by PYC’s kidney asset, due to: a) its elegant mechanism of action, b) orphan indication with a large population (~95k US eligible patients), and c) well-defined, potential accelerated approval pathway.

PYC in February announced that its polycystic kidney disease candidate had approval to escalate dosing in a third cohort of patients following approval from the safety review committee.

Canaccord said, “We are excited to see PYC’s program move into multiple ascending doses”.

We expect an update from the third cohort in the single ascending dose (SAD) portion in May, following which timelines related to the MAD will become clearer, and where the market should be focused.

Canaccord has a price target on PYC shares of $2.84 compared with the current price of $1.33.

PYC Therapeutics is currently valued at $1.28 billion.

The post This ASX biotech stock could more than double Canaccord Genuity says appeared first on The Motley Fool Australia.

More reading

• This ASX biotech stock just jumped again as its lead drug trial moves ahead

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Navigator Global Investments Ltd (ASX: NGI) shares are in focus after the release of a quarterly assets under management (AUM) update.

This led to a 6% share price rise on opening.

At the time of writing, Navigator Global Investments shares are up 2% during today’s session. 

The company remains down more than 17% year to date. 

What did the company report?

Today, the company reported: 

• Navigator’s ownership-adjusted AUM increased by 9% to USD31.6 billion in Q3, up 16% over the last 12 months
• Total NGI Firm Level AUM2 increased by 17% to USD98 billion in Q3, up 20% over the last 12 months
• The Lighthouse Partners business remains the largest contributor, with AUM rising 8% during the quarter to a record US$18.7 billion. Over the past 12 months, that figure is up 17%

The company advised that growth was driven by a mix of inflows and investment performance across its platform.

The company expects strong asset growth (AUM) in Q3 FY26, putting NGI in a good position for FY27.

The company continues to expect FY26 adjusted EBITDA to be lower than FY25, driven by: 

• The timing of AUM growth recognised this quarter
• A higher proportion of inflows into lower fee-generating AUM
• The concentration of NGI’s performance fee revenues, with the majority expected to crystallise in December

This announcement pleased investors, who were gobbling up shares in the company this morning.

What did Morgans have to say?

Following the release, the team at Morgans released updated guidance on Navigator Global Investments shares.

The broker said it was a broadly solid quarter, punctuated by a +9% increase in group Ownership adjusted AUM in a volatile market, and robust quarterly net flows into Lighthouse (+US$1.2bn). 

We update our NGI numbers for the quarterly and also following a broad review of our earnings assumptions. Our FY26F EPS estimate is revised down -3%, reflecting more conservative performance fee assumptions for the current year, while FY27F EPS moves up +2% on higher FUM estimates following today’s update.

Upside and buy rating intact

It appears the company is quickly recovering from an early-year lull. 

Since late March, Navigator Global Investments shares have risen more than 23%. 

It seems that, based on Morgans’ guidance, this recovery can continue. 

Morgans has retained its buy recommendation, along with a largely unchanged price target of $2.97. 

From today’s current price target of $2.46, this indicates an upside potential of approximately 20%. 

The post What is Morgan’s view on Navigator Global Investments shares after update appeared first on The Motley Fool Australia.

More reading

• Why Navigator Global, St Barbara, Vulcan Energy, and Zip shares are racing higher today
• This ASX financial stock is jumping 6% today. Here’s what just landed
• Top brokers name 3 ASX shares to buy next week
• Why these ASX shares are rated as buys in April
• Top brokers name 3 ASX shares to buy today

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is having a subdued session on Tuesday. In afternoon trade, the benchmark index is down 0.25% to 8,932.9 points.

Four ASX shares that are not letting that hold them back today are listed below. Here’s why they are rising:

Artrya Ltd (ASX: AYA)

The Artrya share price is up over 11% to $4.65. This appears to have been driven by a bullish broker note out of Bell Potter this morning. According to the note, the broker has initiated coverage on the medical technology company’s shares with a buy rating and $6.10 price target. It said: “AYA’s unique offering creates an opportunity to achieve rapid growth and a material share of c.4.4m annual CCTA scans in the US market, growing at a CAGR of c.6.2%. AYA has three foundation customers in the US that should deliver c.15k scans annually by FY27. Through the SAPPHIRE study group, AYA has created a warm pipeline of six potential customers and c.400k annual scans that could generate c.10% market share and c.A$450m in annual revenue over the next decade. We expect AYA to reach EBITDA breakeven in FY28.”

Cleanaway Waste Management Ltd (ASX: CWY)

The Cleanaway share price is up 3% to $2.39. This follows the release of the waste management company’s investor day update. Cleanaway unveiled its new Blueprint 2030 2.0 strategy, which is built around three pillars. These are delivering customer value, optimising its branch network, and leveraging advanced ways of working through digital and data capabilities. This includes a major upgrade to sales processes, with a centralised One Sales Engine model that is designed to lift customer retention and cross-sell rates.

DroneShield Ltd (ASX: DRO)

The DroneShield share price is up almost 8% to $3.89. Investors may have been buying the counter-drone technology company’s shares due to concerns that the US and Iran could fail to sign a peace deal before the ceasefire agreement ends. If tensions flare up again in the Middle East, it could lead to increased demand for DroneShield’s suite of products.

Nuix Ltd (ASX: NXL)

The Nuix share price is up 4.5% to $1.32. This follows news that the investigative analytics and intelligence software provider has completed the $27 million acquisition of Linkurious SAS following Foreign Direct Investment (FDI) approval in France. Linkurious provides technology that allows customers to visually explore and investigate graph data, to detect patterns of interest and investigate alerts. Incorporating Annualised Contract Value (ACV) associated with Linkurious, Nuix advises that it now expects full year ACV to be in the range $252 million to $272 million.

The post Why Artrya, Cleanaway, DroneShield, and Nuix shares are pushing higher today appeared first on The Motley Fool Australia.

More reading

• Bell Potter just initiated coverage on this ASX AI stock with a buy rating
• Cleanaway Waste Management shares in focus as strategy refresh targets margin growth
• Where I’d invest $3,000 in ASX growth shares now
• These are the 10 most shorted ASX shares
• ASX 200 tech shares rocket 13% as long-awaited sector rebound accelerates

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield and is short shares of DroneShield. The Motley Fool Australia has recommended Nuix. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.